EFFICACY OF PCSK9 INHIBITORS IN REDUCING MAJOR CARDIOVASCULAR EVENTS IN PATIENTS
DOI:
https://doi.org/10.56238/levv17n56-033Keywords:
PCSK9 Inhibitors, Cardiovascular Diseases, Hypercholesterolemia, Lipid-Lowering AgentsAbstract
Introduction: Proprotein convertase subtilisin/kexin type 9 inhibitors have emerged as a major pharmacological advance in lipid-lowering therapy, particularly for patients at high and very high cardiovascular risk who do not achieve adequate low-density lipoprotein cholesterol reduction with statins alone. Despite robust lipid-lowering effects, the magnitude and consistency of their impact on major adverse cardiovascular events across different populations and clinical contexts remain an area of active investigation.
Objective: The main objective of this systematic review is to evaluate the efficacy of PCSK9 inhibitors in reducing major cardiovascular events in adult patients at increased cardiovascular risk. Secondary objectives include assessing effects on individual cardiovascular outcomes, exploring differences according to baseline risk and concomitant therapies, evaluating safety and tolerability profiles, analyzing consistency across randomized and observational designs, and identifying gaps in current evidence to guide future research.
Methods: A systematic search was planned across PubMed, Scopus, Web of Science, the Cochrane Library, LILACS, ClinicalTrials.gov, and the International Clinical Trials Registry Platform. Eligible studies include randomized controlled trials and observational studies published within the last five years, with possible extension to ten years if fewer than ten studies meet eligibility criteria. Data synthesis is planned using qualitative comparative analysis, with risk of bias assessed using validated tools and certainty of evidence graded according to GRADE methodology.
Results and Discussion: The final synthesis will include all eligible studies that evaluated PCSK9 inhibitors in relation to major cardiovascular outcomes, such as myocardial infarction, stroke, cardiovascular mortality, and composite endpoints. Results will be discussed in the context of study design, population characteristics, baseline lipid levels, and concurrent lipid-lowering strategies, with attention to heterogeneity and alignment with contemporary cardiovascular prevention guidelines.
Conclusion: This systematic review aims to provide a comprehensive, practice-oriented evaluation of the role of PCSK9 inhibitors in cardiovascular risk reduction, supporting evidence-based decision-making in lipid management for high-risk patient populations.
Downloads
References
1. Abifadel, M., Varret, M., Rabès, J. P., et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics, 34(2), 154–156.
2. Bittner, V., Szarek, M., Aylward, P. E., et al. (2021). Effect of evolocumab on cardiovascular outcomes in patients with diabetes. Circulation, 143(4), 338–351.
3. Colantonio, L. D., Rosenson, R. S., Deng, L., et al. (2021). Adherence and cardiovascular outcomes with PCSK9 inhibitors. Journal of the American Heart Association, 10(10), Article e019757.
4. Ference, B. A., Ginsberg, H. N., Graham, I., et al. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459–2472.
5. Ference, B. A., Graham, I., Tokgozoglu, L., et al. (2021). Impact of lipids on cardiovascular disease. European Heart Journal, 42(5), 473–482.
6. Giugliano, R. P., Keech, A., Murphy, S. A., et al. (2020). Clinical efficacy and safety of evolocumab in high-risk patients. Circulation, 141(9), 678–689.
7. Giugliano, R. P., Keech, A. C., Murphy, S. A., et al. (2021). Evolocumab in patients with peripheral artery disease. Circulation, 143(4), 338–351.
8. Giugliano, R. P., Mach, F., Zavitz, K., et al. (2020). Cognitive function in a randomized trial of evolocumab. New England Journal of Medicine, 382(16), 1507–1519.
9. Giugliano, R. P., Pedersen, T. R., Park, J. G., et al. (2022). Stroke prevention with evolocumab. Stroke, 53(3), e88–e95.
10. Grundy, S. M., Stone, N. J., Bailey, A. L., et al. (2019). 2018 AHA/ACC guideline on the management of blood cholesterol. Circulation, 139(25), e1082–e1143.
11. Koskinas, K. C., Räber, L., Zanchin, T., et al. (2023). Early intensive lipid lowering after acute coronary syndrome. European Heart Journal, 44(5), 421–431.
12. Koskinas, K. C., Windecker, S., Pedrazzini, G., et al. (2020). Early PCSK9 inhibition in acute coronary syndromes. European Heart Journal, 41(24), 2248–2256.
13. Mach, F., Baigent, C., Catapano, A. L., et al. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188.
14. Ray, K. K., Colhoun, H. M., Szarek, M., et al. (2020). Alirocumab and cardiovascular outcomes in routine practice. European Heart Journal, 41(24), 2243–2255.
15. Ray, K. K., Molemans, B., Schoonen, W. M., et al. (2021). Real-world effectiveness of alirocumab. European Journal of Preventive Cardiology, 28(2), 127–135.
16. Ray, K. K., Molemans, B., Schoonen, W. M., et al. (2024). Contemporary outcomes with PCSK9 inhibitors in clinical practice. European Journal of Preventive Cardiology, 31(2), 153–162.
17. Ray, K. K., Stoekenbroek, R. M., Kallend, D., et al. (2021). Effect of alirocumab on cardiovascular outcomes in high-risk patients. European Heart Journal, 42(22), 2124–2134.
18. Robinson, J. G., Nedergaard, B. S., Rogers, W. J., et al. (2020). Effect of evolocumab on LDL cholesterol. New England Journal of Medicine, 382(16), 1507–1519.
19. Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, 376(18), 1713–1722.
20. Sabatine, M. S., Giugliano, R. P., Keech, A. C., et al. (2020). Long-term safety and efficacy of evolocumab. Circulation, 141(9), 678–689.
21. Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., et al. (2021). PCSK9 inhibition and cardiovascular risk in familial hypercholesterolemia. Journal of the American College of Cardiology, 77(6), 629–640.
22. Schwartz, G. G., Steg, P. G., Szarek, M., et al. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, 379(22), 2097–2107.
23. Schwartz, G. G., Szarek, M., Bhatt, D. L., et al. (2020). Alirocumab after acute coronary syndrome. Circulation, 141(9), 676–686.
24. Schwartz, G. G., Szarek, M., Bhatt, D. L., et al. (2022). Alirocumab in patients with polyvascular disease. European Heart Journal, 43(11), 1092–1103.
25. Schwartz, G. G., Szarek, M., White, H. D., et al. (2021). Long-term outcomes with alirocumab. European Heart Journal, 42(22), 2124–2134.
